Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials

Critical Reviews in Food Science and Nutrition

Volumn 59, Issue 10, 2019, Pages 1605-1618

  Fogacci, Federica ^a   Tocci, Giuliano ^b,c   Presta, Vivianne ^b,c   Fratter, Andrea ^d   Borghi, Claudio ^a   Cicero, Arrigo F G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d Labomar R D   (Italy)

Author keywords

blood pressure; meta analysis; metaregression; Resveratrol; type 2 diabetes

Indexed keywords

BLOOD PRESSURE; HEALTH; PRESSURE EFFECTS; REGRESSION ANALYSIS;

ACTIVE COMPOUNDS; LITERATURE SEARCH; META ANALYSIS; METAREGRESSION; RANDOMIZED , CONTROLLED CLINICAL TRIAL; SYSTEMATIC REVIEW; TYPE-2 DIABETES; WEIGHTED MEAN DIFFERENCES (WMD);

RESVERATROL;

RESVERATROL;

BLOOD PRESSURE; BODY MASS; COMPLICATION; DIETARY SUPPLEMENT; DRUG EFFECT; DRUG TOLERANCE; FACTUAL DATABASE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS;

BLOOD PRESSURE; BODY MASS INDEX; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DRUG TOLERANCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RESVERATROL;

EID: 85067172801     PISSN: 10408398     EISSN: 15497852     Source Type: Journal    
DOI: 10.1080/10408398.2017.1422480     Document Type: Review

References (46)

1. Anton, S. D., C., Embry, M., Marsiske, X., Lu, H., Doss, C., Leeuwenburgh, and T. M., Manini. 2014. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Experimental Gerontology 57:181–7.
2. Antza, C., I., Doundoulakis, S., Stabouli, and V., Kotsis. 2017. Comparison among recommendations for the management of arterial hypertension issued by last US, Canadian, British and European Guidelines. High Blood Pressure & Cardiovascular Prevention 2017Nov1. doi: 10.1007/s40292-017-0236-x. [Epub ahead of print]
3. Amri, A., J. C., Chaumeil, S., Sfar, and C., Charrueau. 2012. Administration of resveratrol: What formulation solutions to bioavailability limitations? Journal of Controlled Release 158:182–93;
4. Bhatt, J. K., S., Thomas, and M. J., Nanjan. 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research 32:537–41.
5. Borenstein, M., L., Hedges, J., Higgins, and H., Rothstein. 2005. Comprehensive meta-analysis version 3. Englewood, NJ. Biostatistics 2005:104.
6. Borghi, C., and A. F., Cicero. 2017. Nutraceuticals with a clinically detectable blood pressure-lowering effect: A review of available randomized clinical trials and their meta-analyses. British Journal of Clinical Pharmacology 83:163–171.
7. Burnier, M., 2017. Drug adherence in hypertension. Pharmacological Research 125:142–149.
8. Chachay, V. S., G. A., Macdonald, J. H., Martin, J. P., Whitehead, T. M., O'Moore-Sullivan, P., Lee, M., Franklin, K., Klein, P. J., Taylor, M., Ferguson, et al. 2014. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 12:2092–103.e1–6.
9. Chen, S., X., Zhao, L., Ran, J., Wan, X., Wang, Y., Qin, F., Shu, Y., Gao, L., Yuan, Q., Zhang, and M., Mi. 2015. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digestive and Liver Disease 47:226–32.
10. Cicero, A. F., F., Fogacci, and A., Colletti. 2017a. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food and Function 8:2076–2088.
11. Cicero, A. F., A., Colletti, G., Bajraktari, O., Descamps, D. M., Djuric, M., Ezhov, Z., Fras, N., Katsiki, M., Langlois, G., Latkovskis, et al. 2017b. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science 13: 965–1005.
12. Cicero, A. F., and A., Colletti. 2015. Nutraceuticals and blood pressure control: results from clinical trials and meta-analyses. High Blood Pressure and Cardiovascular Prevention 22:203–13.
13. Duval, S., and R., Tweedie. 2000. Trim and fill: a simple funnel‐plot–based method of testing and adjusting for publication bias in meta‐analysis. Biometrics 56:455–63.
14. Faghihzadeh, F., P., Adibi, and A., Hekmatdoost. 2015. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. British Journal of Nutrition 114:796–803.
15. Fogacci, F., A. F. G., Cicero, G., Derosa, M., Rizzo, M., Veronesi, and C., Borghi. 2017. Effect of pistachio on brachial artery diameter and flow-mediated dilatation: a systematic review and meta-analysis of randomized, controlled-feeding clinical studies. Critical Reviews in Food Science and Nutrition 30:0.
16. Follmann, D., P., Elliott, I., Suh, and J., Cutler. 1992. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 45:769–73.
17. Heebøll, S., M., Kreuzfeldt, S., Hamilton-Dutoit, M., Kjær Poulsen, H., Stødkilde-Jørgensen, H. J., Møller, N., Jessen, K., Thorsen, Y., Kristina Hellberg, S., Bønløkke Pedersen, et al. 2016. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 51:456–64.
18. Higgins, J., S., Green. 2010. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0. 2. 2009. Chichester, UK, John Wiley and Sons Ltd.
19. Hozo, S. P., B., Djulbegovic, and I., Hozo. 2005. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 5:13.
20. Imamura, H., T., Yamaguchi, D., Nagayama, A., Saiki, K., Shirai, and I., Tatsuno. 2017. Resveratrol ameliorates arterial stiffness assessed by cardio-ankle vascular index in patients with Type 2 diabetes mellitus. International Heart Journal 58:577–583.
21. Kumar, B. J., and N. M., Joghee. 2013. Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. International Research Journal of Pharmacy 4:245–249.
22. Kjær, T. N., M. J., Ornstrup, M. M., Poulsen, H., Stødkilde-Jørgensen, N., Jessen, J. O. L., Jørgensen, B., Richelsen, and S. B., Pedersen. 2017. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. The Journal of Clinical Endocrinology and Metabolism 102:1642–1651.
23. Li, H., N., Xia, and U., Förstermann. 2012. Cardiovascular effects and molecular targets of resveratrol. Nitric oxide 26:102–10.
24. Liu, Y., W., Ma, P., Zhang, S., He, and D., Huang. 2015. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clinical Nutrition 34: 27–34.
25. Méndez-del Villar, M., M., González-Ortiz, E., Martínez-Abundis, K. G., Pérez-Rubio, and R., Lizárraga-Valdez. 2014. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metabolic Syndrome and Related Disorders 12:497–501.
26. Moher, D., A., Liberati, J., Tetzlaff, and D. G., Altman, P. R. I. S. M. A., Group. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. The BMJ 339:b2535.
27. Movahed, A., I., Nabipour, X., Lieben Louis, S. J., Thandapilly, L., Yu, M., Kalantarhormozi, S. J., Rekabpour, and T., Netticadan. 2013. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine 2013:851267.
28. Newman, J. D., A. Z., Schwartzbard, H. S., Weintraub, I. J., Goldberg, and J. S., Berger. 2017. Primary prevention of cardiovascular disease in diabetes mellitus. Journal of the American College of Cardiology 70:883–893.
29. Ornstrup, M. J., T., Harsløf, T. N., Kjær, B. L., Langdahl, and S. B., Pedersen. 2014. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism 99:4720–9.
30. Rochlani, Y., M. H., Khan, and W. S., Aronow. 2017. Managing hypertension in patients aged 75 years and older. Current Hypertension Reports 19:88.
31. Sahebkar, A., M., Pirro, M., Banach, D. P., Mikhailidis, S. L., Atkin, and A. F. G., Cicero. 2017. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition 13:1–8.
32. Sahebkar, A., Ž. Reiner, L. E., Simental-Mendía, G., Ferretti, and A. F., Cicero. 2016. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism 65:1664–1678.
33. Sahebkar, A., C., Serban, S., Ursoniu, N. D., Wong, P., Muntner, I. M., Graham, D. P., Mikhailidis, M., Rizzo, J., Rysz, L. S., Sperling, G. Y., Lip, and M., Banach, Lipid and Blood Pressure Meta-analysis Collaboration Group. 2015. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors–Results from a systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology 189: 47–55.
34. Serban, M. C., A., Sahebkar, A., Zanchetti, D. P., Mikhailidis, G., Howard, D., Antal, F., Andrica, A., Ahmed, W. S., Aronow, P., Muntner, G. Y., Lip, I., Graham, N., Wong, J., Rysz, and M., Banach, Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group. 2016. Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association 5:pii: e002713.
35. Sergides, C., M., Chirilă, L., Silvestro, D., Pitta, and A., Pittas. 2016. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Experimental and Therapeutic Medicine 11:164–170.
36. Sirtori, C. R., A., Arnoldi, and A. F., Cicero. 2015. Nutraceuticals for blood pressure control. Annals of Medicine 47:447–56.
37. Sosnowska, B., P., Penson, and M., Banach. The role of nutraceuticals in the prevention of cardiovascular disease. 2017. Cardiovascular Diagnosis and Therapy 7(Suppl 1):S21–S31.
38. Tomé-Carneiro, J., M., Gonzálvez, M., Larrosa, M. J., Yáñez-Gascón, F. J., García-Almagro, J. A., Ruiz-Ros, F. A., Tomás-Barberán, M. T., García-Conesa, and J. C., Espín. 2013. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovascular Drugs and Therapy 27:37–48.
39. Timmers, S., M., de Ligt, E., Phielix, T., van de Weijer, J., Hansen, E., Moonen-Kornips, G., Schaart, I., Kunz, M. K., Hesselink, V. B., Schrauwen-Hinderling, et al. 2016. Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial. Diabetes Care 39:2211–2217.
40. Timmers, S., E., Konings, L., Bilet, R. H., Houtkooper, T., van de Weijer, G. H., Goossens, J., Hoeks, S., van der Krieken, D., Ryu, S., Kersten, et al. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism 14:612–22.
41. van der Made, S. M., J., Plat, and R. P., Mensink. 2015. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One 10:e0118393.
42. Walle, T., F., Hsieh, M. H., DeLegge, J. E., Oatis Jr, and U. K., Walle. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition 32:1377–82. Epub 2004Aug27;
43. Walle, T., 2011. Bioavailability of resveratrol. Annals of the New York Academy of Sciences 2011;1215:9–15.
44. Wong, R. H., N. M., Berry, A. M., Coates, J. D., Buckley, J., Bryan, I., Kunz, and P. R., Howe. 2013. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. Journal of Hypertension 31:1819–27.
45. Yoshino, J., C., Conte, L., Fontana, B., Mittendorfer, S., Imai, K. B., Schechtman, C., Gu, I., Kunz, F., Rossi Fanelli, B. W., Patterson, et al. 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism 16:658–64.
46. Zhu, X., C., Wu, S., Qiu, X., Yuan, and L., Li. 2017. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutrition and Metabolism 14:60.